Chromothripsis

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on: 
Wednesday, April 3, 2024
Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points: 
  • Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
  • The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
  • In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
  • As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and ​comprehensive, genome-wide analysis.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress

Retrieved on: 
Thursday, November 3, 2022
Chronic lymphocytic leukemia, DNA, Society, Potency (pharmacology), IPSC, Cerebellar ataxia, BMA, Regenerative medicine, MD Anderson Cancer Center, Schizophrenia, CRISPR, Company, Infertility, Workflow, Study, Growth, SAN, GAAP, OGM, GLOBE, Total, Ataxia, Genomics, LDT, ASHG, Chromothripsis, Patient, Cancer, CLL, Doctor of Philosophy, MDS, Long, SVS, Research, Hospital, Human genetics, Lineagen, Sale, International Cancer Genome Consortium, Pregnancy loss, NIPT, CTH, Adoption, Long-string instrument, UHMW, American Society of Human Genetics, Chromosome, ATM, RPL, Industry, Microdeletion syndrome, Publication, Certification, Tumors of the hematopoietic and lymphoid tissues, Acute myeloid leukemia, Nasdaq, Peripheral neuropathy, Karyotype, TP53, AML, RFC1, Renewable energy, Video game, Pharmaceutical industry, Medical imaging

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • milestones
    Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022
    SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September30, 2022.
  • We believe our Q3 2022 results, which include the highest quarterly revenues ever for Bionano, reflect continued gains in market development and commercial validation for OGM.
  • Total revenue for Q3 2022 was $7.2 million, up 55% from Q3 2021, and an 8% increase from Q2 2022.
  • Chris Stewart, chief financial officer of Bionano added, Q3 2022 was another outstanding quarter for Bionano.

Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Retrieved on: 
Thursday, August 25, 2022
Software, Security (finance), COVID-19, CBA, Research, SAN, Doctor of Philosophy, Solution, Chronic lymphocytic leukemia, CMA, OGM, CLL, Central Statistics Office (India), Hospital, CTH, Genomics, Genome, U.S. Securities and Exchange Commission, Chromothripsis, GLOBE, Classification, Medicine, Biology, Nasdaq, Company, Lineagen, TP53, Chromosome, Annual report, Private Securities Litigation Reform Act, Autism, Hospital Insurance and Diagnostic Services Act, Forward-looking statement, Adoption, Patient, Medical device, Medical imaging, Risk management, Cancer

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity.

Key Points: 
  • SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity.
  • The study compared the cytogenomic aberrations observed by genomic microarrays and chromosome banding analysis (CBA) to those observed using OGM.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
  • Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM to analyze chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity.

Bionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies

Retrieved on: 
Tuesday, January 11, 2022
Medicine, CLL, Research, T-Cell Acute Lymphoblastic Leukemia, SAN, Private Securities Litigation Reform Act, Genome, AML, Standard of care, Leukemia, U.S. Securities and Exchange Commission, Karyotype, Hospital, Hospital Insurance and Diagnostic Services Act, OGM, Cancer, Hannover Medical School, COVID-19, Adoption, Adult, Neoplasm, University Hospitals Cleveland Medical Center, Lymphatic system, Chromothripsis, Company, Method, Doctor of Philosophy, Blood, Annual report, Chronic lymphocytic leukemia, Forward-looking statement, Patient, Biology, All of Us (initiative), Genomics, Solution, Lineagen, Malignancy, Software, Workflow, FACMG, NGS, Lymphocytosis, Marker beacon, ALL, GLOBE, MLPA, Bone marrow, Autism, Acute myeloid leukemia, Security (finance), Medical imaging, Vaccine, Medical device, FISH, Quest Diagnostics

Ten presentations from leading researchers across North America and Europe showcased the utility of OGM for hematologic malignancies at 2022 Symposium.

Key Points: 
  • Ten presentations from leading researchers across North America and Europe showcased the utility of OGM for hematologic malignancies at 2022 Symposium.
  • These researchers also shared examples of novel variants of potential clinical importance discovered with OGM that were undetected with other methods.
  • OGM revealed novel genetic aberrations in B-cell Chronic Lymphocytic Leukemia (B-CLL) and Acute Lymphoblastic Leukemias (ALL).
  • OGM detected more clinically relevant variants across a wide range of hematologic malignancies including acute myeloid leukemia (AML).

Bionano Genomics Announces Peer-Reviewed Publication from Johns Hopkins University Outlining a Stepwise Approach to the Adoption of Optical Genome Mapping for Cancer Analysis

Retrieved on: 
Monday, November 22, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), SV, Adoption, Protein, Disease, Leukemia, Annual report, Genome, Company, Biology, Chromothripsis, Diagnosis, Genomics, SVS, CNV, Gene expression, Forward-looking statement, SAN, Solution, U.S. Securities and Exchange Commission, COVID-19, NGS, Software, Karyotype, Research, GLOBE, Collection, OGM, Pathology, Hospital Insurance and Diagnostic Services Act, Bone marrow, CMA, Journal, MBP, Lineagen, NanoString Technologies, Medicine, Autism, Johns Hopkins University, Method, Gene, Medical imaging

Sensitivity compared to CMA was 96% (22/23 CNVs detected) excluding copy neutral loss of heterozygosity calls.

Key Points: 
  • Sensitivity compared to CMA was 96% (22/23 CNVs detected) excluding copy neutral loss of heterozygosity calls.
  • OGM was also used in the study to provide high resolution analysis of subjects with complex karyotypes exhibiting chromothripsis.
  • Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.